Tofacitinib

Upper respiratory tract infection: case report

In a retrospective observational study of 10 patients conducted between June 2018 and April 2019 at a hospital in Poland, a patient [age and sex not stated] was described, who developed recurrent upper respiratory tract infection during treatment with oral tofacitinib 5mg twice a day for rheumatoid arthritis. The patient presented with symptoms of mild and moderate severity approximately 4 months after initiation of tofacitinib. The patient was treated with amoxicillin, cefuroxime and clarithromycin. However, a slight improvement was noted. Eventually, tofacitinib was stopped, and the symptoms resolved.

Author comment: "In one patient symptoms of chronic upper respiratory tract infection led to discontinuation of the drug."

Madej M, et al. Tofacitinib in the treatment of active rheumatoid arthritis - Single-centre experience. Reumatologia 57: 192-198, No. 4, 2019. Available from: URL: http://doi.org/10.5114/reum.2019.87609 - Poland